Retrospective Study on Ganglionic and Nerve Block Series as Therapeutic Option for Chronic Pain Patients with Refractory Neuropathic Pain
Table 2
Logistic regression analyses.
Univariate regression analysis
Multivariate regression analysis
OR (95% SD)
OR (95% SD)
A
Female sex
0.684 (0.261–1.791)
0.440
Corticoid use during infiltration
1.156 (0.357–3.750)
0.809
Age
1.045 (1.012–1.080)
0.007
1.052 (1.009–1.098)
0.018
Months in pain until the first visit
1.004 (0.996–1.011)
0.347
Cotherapy opioids
0.552 (0.215–1.413)
0.215
Cotherapy antidepressants
1.000 (0.315–3.174)
>0.999
Cotherapy antiepileptics
1.000 (0.157–6.373)
>0.999
Improvement after the first infiltration
4.833 (1.562–14.955)
0.006
Improvement after the first two infiltrations
8.017 (2.431–26.436)
0.001
7.484 (2.089–26.816)
0.002
B
Female sex
0.682 (0.268–1.737)
0.423
Corticoid use during infiltration
1.378 (0.427–4.46)
0.592
Age
1.034 (1.004–1.066)
0.029
1.061 (1.016–1.108)
0.008
Months in pain until the first visit
1.007 (0.999–1.015)
0.079
1.011 (1.011–1.021)
0.024
Cotherapy opioids
0.602 (0.238–1.522)
0.284
Cotherapy antidepressants
0.819 (0.263–2.543)
0.729
Cotherapy antiepileptics
0.630 (0.099–4.003)
0.624
Improvement after the first infiltration
2.413 (0.858–6.781)
0.095
Improvement after the first two infiltrations
3.491 (1.125–10.829)
0.030
3.579 (0.898–14.255)
0.071
Univariate and multivariate logistic regression analyses were used to predict a clinical response of at least 30% (A) and a pain reduction of 50% (B) as dependent variable. Multivariate analysis was performed with variables of at least in univariate testing. Hosmer–Lemeshow goodness-of-fit test was sufficiently for multivariate regression model (A: Chi2 12.056, ;N = 66; B: Chi2 8.763, ;N = 61).
